COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities

Frontiers in Medicine

Daniel A. Culver¹  Michael Manansala²  Robert P. Baughman³  Elyse E. Lower³  Peter Korsten⁴  Richard Novak⁵  Wonder P. Drake⁶  Amit Chopra⁷  Marc A. Judson⁷  Nadera Sweiss⁸ 

[1] Cleveland Clinic, Department of Pulmonary Medicine, Cleveland, OH, United States;Department of Medicine, Academic Internal Medicine, University of Illinois at Chicago, Chicago, IL, United States;Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, United States;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany;Division of Infectious Disease, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States;Division of Infectious Disease, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States;Division of Pulmonary and Critical Care Medicine, Department of Medicine, Albany Medical College, Albany, NY, United States;Division of Rheumatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States;

关键词: coronavirus – COVID-19;    sarcoidosis;    vaccination;    immunosuppression;    SARS-CoV-2;   

DOI  :  10.3389/fmed.2021.672028

来源: Frontiers

【 摘 要 】

Sarcoidosis is an immune mediated chronic inflammatory disorder that is best characterized by non-caseating granulomas found in one or more affected organs. The COVID-19 pandemic poses a challenge for clinicians caring for sarcoidosis patients who may be at increased risk of infection compared to the general population. With the recent availability of COVID-19 vaccines, it is expected that clinicians raise questions regarding efficacy and safety in sarcoidosis. However, studies examining safety and efficacy of vaccines in sarcoidosis are lacking. In this review, we examine the current literature regarding vaccination in immunocompromised populations and apply them to sarcoidosis patients. The available literature suggests that vaccines are safe and effective in patients with autoimmune disorders and in those taking immunosuppressive medications. We strongly recommend the administration of COVID-19 vaccines in patients with sarcoidosis. We also present a clinical decision algorithm to provide guidance on vaccination of sarcoidosis patients against COVID-19.

【 授权许可】

CC BY